|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2011
|
|
gptkbp:ATCCode
|
B01AC24
|
|
gptkbp:brand
|
gptkb:Brilique
gptkb:Possia
|
|
gptkbp:CASNumber
|
274693-27-5
|
|
gptkbp:chemicalFormula
|
C23H28F2N6O4S
|
|
gptkbp:contraindication
|
severe hepatic impairment
active bleeding
history of intracranial hemorrhage
|
|
gptkbp:drugClass
|
gptkb:anticoagulant
|
|
gptkbp:eliminatedIn
|
urine
feces
|
|
gptkbp:genericName
|
gptkb:ticagrelor
|
|
gptkbp:halfLife
|
7 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Brilinta
|
|
gptkbp:interactsWith
|
gptkb:digoxin
statins
strong CYP3A4 inducers
strong CYP3A4 inhibitors
|
|
gptkbp:legalStatus
|
Rx-only (US)
|
|
gptkbp:manufacturer
|
gptkb:AstraZeneca
|
|
gptkbp:mechanismOfAction
|
P2Y12 receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
bleeding
bradycardia
dyspnea
|
|
gptkbp:usedFor
|
gptkb:acute_coronary_syndrome
myocardial infarction
prevention of thrombotic events
|
|
gptkbp:bfsParent
|
gptkb:AstraZeneca
|
|
gptkbp:bfsLayer
|
5
|